Virchow Biotech
Biosimilar developer, India. 2 development products across 2 molecules: pegfilgrastim, rituximab.
Portfolio by market
| Molecule | Product | FDA | EMA | MHRA | PMDA | HC | CDSCO | EDE | Markets |
|---|---|---|---|---|---|---|---|---|---|
| Pegfilgrastim | Virchow Biotech pegfilgrastim | · | · | · | · | · | Dec 2021 | · | 1/7 |
| Rituximab | Virchow Biotech rituximab | · | · | · | · | · | Aug 2025 | · | 1/7 |
Month shown is the first approval or registration of that product in that market.
Companies on the same molecules
Developers whose portfolios overlap most with Virchow Biotech, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.
Chronology
- CDSCODec 2021Virchow Biotech (INN only), pegfilgrastim
- CDSCOAug 2025Virchow Biotech Private (INN only), rituximab
Compare Virchow Biotech with other developers on the comparison page.
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant